Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 30, Number 9—September 2024
Dispatch
Epidemiology of Lyme Disease Diagnoses among Older Adults, United States, 2016–20191
Amy M. Schwartz, Christina A. Nelson, and Alison F. Hinckley
Table
Characteristics of Lyme disease diagnoses according to Medicare fee-for-service claims data versus cases identified by national surveillance in a population of persons > 65 years of age, United States, 2016–2019*
| Characteristic | High-incidence states |
Neighboring states |
Low-incidence states |
|||||
|---|---|---|---|---|---|---|---|---|
| Medicare | Surveillance | Medicare | Surveillance | Medicare | Surveillance | |||
| Person-years | 72,298 | NA | 5,958 | NA | 10,009 | NA | ||
| Diagnoses or cases, no. | 72,455 | 31,879 | 5,978 | 1,714 | 10,052 | 590 | ||
| Diagnoses or cases, % | 81.9 | 93.3 | 6.7 | 5.0 | 11.3 | 1.7 | ||
| Incidence among men | 422.9 | 71.0 | 38.3 | 4.6 | 30.1 | 0.6 | ||
| Incidence among women | 321.3 | 46.6 | 33.4 | 3.0 | 29.2 | 0.5 | ||
| Occurring in May–August, % | 59.5 | 72.2 | 58.2 | 79.9 | 45.8 | 66.2 | ||
| Median incidence 2016–2019 (range) | 346.9 (337.2–417.8) | 57.1 (52.9–65.6) | 35.3 (27.9–36.6) | 3.6 (2.4–5.3) | 29.4 (27.7–31.6) | 0.6 (0.5–0.6) | ||
*Incidence calculated as diagnoses/100,000 person-years in Medicare fee-for-service or cases/100,000 population among each surveillance subcategory. NA, not applicable
1Preliminary results from this study were presented at the International Conference on Emerging Infectious Diseases; August 7–10, 2022, Atlanta, Georgia, USA.
Page created: August 13, 2024
Page updated: August 13, 2024
Page reviewed: August 13, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.